Tscan Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Tscan Therapeutics, Inc. had total assets of $229m, total liabilities of $106m and shareholders' equity of $123m. It held $152m in cash against $32.5m of debt: net cash of $120m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Tscan Therapeutics, Inc.: balance sheet, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash and equivalents	35	161	120	133	179	152	100
Total current assets	36	166	124	194	293	157	104
Total assets	50	188	199	272	371	229	171
Accounts payable	3	2	3	2	4	1	3
Deferred revenue (current)	11	11	4	10	12	3	1
Total current liabilities	17	21	17	30	36	19	31
Short-term debt	—	—	—	3	—	—	12
Long-term debt	—	—	29	27	32	33	21
Total debt	0	0	30	30	33	33	33
Total liabilities	33	27	100	121	130	106	102
Shareholders' equity	−42	161	99	151	241	123	69
Non-controlling interests and other (assets − liabilities − equity)	60	—	—	—	—	—	—
Net debt (negative = net cash)	−35	−161	−90	−103	−146	−120	−67

US$ millions unless shown otherwise. Fiscal quarters.

Tscan Therapeutics, Inc.: balance sheet, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Total current assets	274	293	255	221	188	157	133	104
Total assets	348	371	333	299	262	229	202	171
Accounts payable	4	4	5	5	6	1	2	3
Deferred revenue (current)	10	12	10	8	5	3	2	1
Total current liabilities	29	36	30	31	29	19	20	31
Short-term debt	—	—	—	—	—	—	—	12
Long-term debt	31	32	32	32	32	33	33	21
Total debt	31	32	32	32	32	33	33	33
Total liabilities	119	130	123	122	118	106	105	102
Shareholders' equity	229	241	210	177	144	123	97	69

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: EVAX vs TCRX ROIV vs TCRX HCWB vs TCRX FATE vs TCRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Tscan Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tscan Therapeutics, Inc.